Portfolio
In addition to our latest blogs on biosimilars from our sister site (www.biosimilarsrr.com), here is a sampling of recent publications and articles developed by SM Health Communications LLC, by category.
White Papers/Comprehensive Reports
Deep dives into focused topics, involving healthcare policy.
Mehr SR: The US Biosimilar Market: A History of Growth and Towards a Sustainable Future. January 2023 https://biosimilarsrr.com/our-biosimilars-market-report/.
Mehr SR: Where the US Biosimilars Market Is Heading and When It Might Get There, Eds 1 & 2. February 2020 and January 2021.
Mehr SR, Renfro M: The Patient’s Paramount Place: Emphasis on Empowerment, Engagement, Experience. Academy of Managed Care Pharmacy Foundation. August 2018.
Mehr SR, Reinert A: The Rx affordability crisis. Academy of Managed Care Pharmacy Foundation. September 2017.
Mehr SR: AMCP Market Insights: Focus on Psoriasis. American Medical Communications, Manalpan, NJ, June 2016.
The Biotechnology Monitor and Survey, Eds 1 & 2. Wayne, New Jersey, Emron, Inc, 2008 and 2009.
Tina Witte
Senior Associate Director
Fletcher Hospital and Healthcare Solutions
Articles Published
Papers appearing in peer-reviewed journals.
Mehr SR: Which Biosimilar Companies Will Thrive in 2025? Biosimilar Development March 31, 2020. https://www.biosimilardevelopment.com/doc/which-biosimilar-companies-will-thrive-in-0001.
Mehr SR, Brook RA: Biosimilars in the USA: Will new efforts to spur approvals and access spur uptake and cost savings? Pharmaceutical Medicine 2019; https://doi.org/10.1007/s40290-018-00262-z.
Mehr SR: Can the FTC Clear a Path for Biosimilar Access Through the Patent Thicket? Biosimilar Development June 4, 2019. https://www.biosimilardevelopment.com/doc/can-the-ftc-clear-a-path-for-biosimilar-access-through-the-patent-thicket-0001.
Medicare’s International Pricing Index–Biosimilar Stakeholders Weigh In. Biosimilar Development February 19, 2019. https://www.biosimilardevelopment.com/doc/medicare-s-international-pricing-index-biosimilar-stakeholders-weigh-in-0001.
Mehr SR: If four-letter suffixes aren’t used in biosimilar tracking, what use are they? Biosimilar Development. November 6, 2018. https://www.biosimilardevelopment.com/doc/if-four-letter-suffixes-aren-t-used-in-biosimilar-tracking-what-use-are-they-0001.
Mehr SR: Will the PCSK9 inhibitors be employers’ “line in the sand”? Am Health Drug Benefits 2016;9(3):171-174.
Mehr SR: The Top 5 Health Benefits/Delivery Trends Affecting Oncology Business Practices. Oncology Practice Management 2016;2(6).
Mehr SR, Zimmerman MP: Reviewing the Unmet Needs in Multiple Sclerosis. Am Health Drug Benefits. 2015;8(8):426-431.
Radick L, Mehr SR: The Latest Innovations and the Phase 3 Pipeline for Multiple Sclerosis. Am Health Drug Benefits 2015;8(8):448-453.
Uncredited Works
Articles developed for on-line and print publishers without a byline.
Rett Syndrome. CheckRare February 6, 2023. https://checkrare.com/rett-syndrome/
Type 1 Galactosemia: Significant Unmet Need, Lifelong Complications, and Current Management. CheckRare March 30, 2022. https://checkrare.com/galactosemia-disease-resource-center/
Niemann-Pick Disease Type C. CheckRare November 17, 2020. https://checkrare.com/niemann-pick-disease-type-c/.
Angelman Syndrome. CheckRare November 17, 2020. https://checkrare.com/angelman-syndrome/
Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency. CheckRare November 17, 2020. https://checkrare.com/aromatic-l-amino-acid-decarboxylase-aadc-deficiency/.
